https://rijournals.com/public-health-and-pharmacy/

RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY 3(3): 1-9, 2024

RIJPP Publications

ISSN ONLINE: 1115-8689

ISSN PRINT 1597-8559

https://doi.org/10.59298/RIJPP/2024/3319

Epigenetic Modifications and Diabetes: Unraveling the Interplay between Genetics, Lifestyle, and Disease Progression

Kato Jumba K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Epigenetic modifications are increasingly recognized as critical factors in the pathogenesis and progression of diabetes, particularly type 2 diabetes mellitus (T2DM). This review examined the complex interplay between genetic predispositions, lifestyle factors, and epigenetic changes that contributed to the development of diabetes and its complications. Key epigenetic mechanisms, including DNA methylation, histone modifications, and non-coding RNAs, can alter gene expression without changing the underlying DNA sequence, thereby influencing metabolic pathways essential for insulin sensitivity and β-cell function. Environmental factors such as diet, physical activity, and exposure to toxins induced epigenetic alterations, linking lifestyle choices to diabetes risk. Moreover, these modifications had significant implications for the development of microvascular and macrovascular complications associated with diabetes, including retinopathy and cardiovascular disease. Understanding the epigenetic landscape of diabetes not only enhanced our comprehension of its underlying mechanisms but also opened new avenues for therapeutic interventions. This review synthesized findings from recent literature and highlights the potential for targeting epigenetic modifications in developing personalized treatment strategies. A comprehensive analysis of studies published over the last decade, focusing on the relationship between epigenetics and diabetes.

Keywords: Epigenetics, Type 2 Diabetes Mellitus (T2DM), DNA Methylation, Lifestyle Factors, Diabetic Complications.

INTRODUCTION

Diabetes mellitus, particularly type 2 diabetes (T2DM), has emerged as a global health crisis, with projections indicating that its prevalence will continue to rise significantly in the coming decades [1,2]. This metabolic disorder is characterized by chronic hyperglycemia resulting from insulin resistance and impaired insulin secretion [3]. While genetic predisposition plays a crucial role in diabetes susceptibility, recent research has highlighted the importance of epigenetic modifications as a key mechanism through which environmental factors, including lifestyle choices, influence disease progression [4,5]. Epigenetics refers to heritable changes in gene expression that occur without alterations to the underlying DNA sequence [6]. These modifications include DNA methylation, histone modifications, and the regulation by non-coding RNAs, all of which can profoundly affect cellular function and contribute to the pathophysiology of diabetes [7]. For instance, DNA methylation patterns can regulate genes involved in insulin signaling and glucose metabolism, while histone modifications can alter chromatin structure, impacting gene accessibility and transcriptional activity. Non-coding RNAs, such as microRNAs, have also been implicated in the regulation of metabolic pathways relevant to diabetes [8]. The interplay between genetics, lifestyle, and epigenetic modifications creates a complex landscape that influences not

only the onset of diabetes but also its complications, such as cardiovascular disease, nephropathy, and retinopathy [9,10]. Environmental factors like diet, physical activity, and exposure to toxins can induce epigenetic changes that modulate gene expression, thereby affecting an individual's risk of developing diabetes and its associated complications [11,12]. Understanding these epigenetic mechanisms provides valuable insights into the multifaceted nature of diabetes and highlights potential therapeutic targets. By unraveling the intricate relationship between genetic predispositions and lifestyle factors through the lens of epigenetics, researchers can develop more effective prevention and treatment strategies tailored to individual risk profiles. This review aims to explore the current understanding of epigenetic modifications in diabetes, emphasizing their role in linking genetic and environmental influences to disease progression and highlighting the therapeutic implications of these findings.

EPIGENETIC MECHANISMS IN DIABETES PATHOGENESIS

Epigenetic mechanisms play a crucial role in the pathogenesis of diabetes, particularly in type 2 diabetes mellitus (T2DM). These mechanisms, which include DNA methylation, histone modifications, and the action of non-coding RNAs, influence gene expression without altering the underlying DNA sequence. This allows for the regulation of key metabolic processes that are critical for maintaining glucose homeostasis.

Key Epigenetic Modifications in Diabetes

i. ***DNA Methylation:*** Methylation of cytosine residues in CpG islands is a significant epigenetic modification associated with T2DM. Altered DNA methylation patterns have been observed in genes crucial for insulin action and secretion, such as PPARG, KCNQ1, and IRS1. Increased methylation in pancreatic β-cells leads to decreased expression of insulin and other key regulatory genes, contributing to impaired insulin secretion and β-cell dysfunction [13,14].

ii. ***Histone Modifications:*** Post-translational modifications of histones, including acetylation and methylation, also play a pivotal role in diabetes pathogenesis [15]. Histone acetylation typically enhances gene expression by making chromatin more accessible, while methylation can either activate or repress gene transcription depending on the specific context. Dysregulation of these modifications can lead to altered expression of genes involved in insulin signaling and glucose metabolism, exacerbating insulin resistance and metabolic dysfunction [16].

iii. ***Non-Coding RNAs:*** Non-coding RNAs, particularly microRNAs, have emerged as important regulators of gene expression in diabetes. These molecules can modulate the expression of genes involved in insulin signaling pathways, inflammation, and oxidative stress. For example, certain microRNAs have been shown to target genes that regulate insulin sensitivity, thereby influencing the development of insulin resistance and β-cell dysfunction [17].

Environmental Influences on Epigenetic Changes: The interplay between genetic predisposition and environmental factors is critical in the context of diabetes [18]. Lifestyle factors such as diet, physical activity, and exposure to toxins can induce epigenetic changes that predispose individuals to T2DM. For instance, high-fat diets and obesity have been linked to specific epigenetic modifications that promote insulin resistance and inflammation, further complicating the disease's pathology [19,20].

Implications for Therapeutics: Understanding the epigenetic mechanisms underlying diabetes opens new avenues for therapeutic interventions [21]. Targeting specific epigenetic modifications could lead to novel treatment strategies aimed at reversing the pathological changes associated with T2DM. For example, drugs that modify histone acetylation or methylation patterns are being explored as potential therapies to restore normal gene expression and improve metabolic outcomes [22,23].

INTERPLAY BETWEEN GENETICS, LIFESTYLE, AND EPIGENETICS

The interplay between genetics, lifestyle, and epigenetics is a complex and dynamic relationship that significantly influences health outcomes, particularly in the context of diseases like diabetes. Genetic predispositions provide a foundational risk for developing diabetes; however, environmental factors and lifestyle choices can modulate this risk through epigenetic mechanisms.

i. **Genetic Contributions:** Genetics plays a crucial role in determining an individual's susceptibility to diabetes [24]. Numerous genetic variants have been identified that are associated with increased risk for type 2 diabetes (T2DM). These genetic factors can influence metabolic pathways, insulin sensitivity, and β-cell function. However, the mere presence of these genetic predispositions does not guarantee disease development; rather, they interact with environmental and lifestyle factors to manifest in health outcomes [25,26].

ii. **Lifestyle Factors and Their Impact:** Lifestyle choices, including diet, physical activity, smoking, and alcohol consumption, can significantly impact an individual's health and the expression of genetic predispositions [27]. For instance, a diet high in processed sugars and fats can exacerbate insulin resistance, while regular physical activity can enhance metabolic health. These lifestyle factors can induce epigenetic changes, such as alterations in DNA methylation and histone modifications, which can subsequently influence gene expression related to glucose metabolism and insulin signaling [28].

iii. **Epigenetic Mechanisms:** Epigenetic modifications serve as a bridge between genetic predispositions and lifestyle factors [29]. They allow for the flexible regulation of gene expression in response to environmental stimuli without altering the genetic code itself. For example, dietary components like folate and polyunsaturated fatty acids can lead to changes in DNA methylation patterns that affect genes involved in metabolic processes. Similarly, chronic stress and obesity can induce epigenetic changes that promote inflammation and insulin resistance, further complicating the pathogenesis of diabetes [30,31].

iv. **Transgenerational Effects:** Another significant aspect of the interplay between genetics, lifestyle, and epigenetics is the potential for transgenerational effects. Epigenetic modifications can be passed down to subsequent generations, meaning that the lifestyle choices of one generation can influence the health of future generations [32]. This phenomenon highlights the importance of considering both current lifestyle choices and historical environmental exposures when assessing disease risk [33].

EPIGENETIC MODIFICATIONS AND DIABETIC COMPLICATIONS

Diabetes, particularly type 2 diabetes (T2DM), is a complex metabolic disorder characterized by chronic hyperglycemia, insulin resistance, and impaired insulin secretion. While genetic predisposition plays a significant role in diabetes susceptibility, epigenetic modifications have emerged as crucial mechanisms linking genetic and environmental factors to the development and progression of diabetic complications [34,35]. These epigenetic changes, including DNA methylation, histone modifications, and non-coding RNAs, can alter gene expression without altering the underlying DNA sequence, thereby influencing the risk and severity of diabetic complications.

i. **DNA Methylation and Diabetic Complications:** DNA methylation, particularly in CpG-rich regions, is a key epigenetic modification associated with diabetic complications [36]. Altered DNA methylation patterns have been observed in genes involved in inflammation, oxidative stress, and fibrosis, which are common features of diabetic complications. For example, increased methylation of the TXNIP gene in the retinas of diabetic rats has been linked to the development of diabetic retinopathy [37]. Similarly, hypermethylation of the *SOD2* gene, which encodes an antioxidant enzyme, has been associated with increased oxidative stress and the progression of diabetic nephropathy [38].

ii. **Histone Modifications and Diabetic Complications:** Post-translational modifications of histones, such as acetylation and methylation, also play a significant role in the pathogenesis of diabetic complications [39]. Histone acetylation typically enhances gene expression, while methylation can either activate or repress transcription depending on the specific context. Dysregulation of these modifications can lead to altered expression of genes involved in inflammation, apoptosis, and cellular senescence, contributing to the development of diabetic complications. For instance, hyperacetylation of histone H3 has been linked to the upregulation of inflammatory genes in the kidneys of diabetic mice, promoting the progression of diabetic nephropathy [40].

iii. **Non-Coding RNAs and Diabetic Complications:** Non-coding RNAs, particularly microRNAs (miRNAs), have emerged as important regulators of gene expression in diabetic complications [41]. These small RNA molecules can modulate the expression of genes involved in various pathways,

including insulin signaling, inflammation, and angiogenesis [42]. Altered expression of specific miRNAs has been associated with the development of diabetic retinopathy, nephropathy, and cardiovascular complications. For instance, upregulation of miR-29b has been linked to increased apoptosis of retinal cells in diabetic retinopathy, while downregulation of miR-192 has been implicated in the development of diabetic nephropathy [43,44].

iv. **Therapeutic Implications:** Understanding the epigenetic mechanisms underlying diabetic complications opens new avenues for therapeutic interventions [45]. Targeting specific epigenetic modifications could lead to novel treatment strategies aimed at reversing the pathological changes associated with diabetic complications. For example, drugs that modify DNA methylation or histone acetylation patterns are being explored as potential therapies to restore normal gene expression and improve clinical outcomes. Additionally, modulating the expression of specific miRNAs using antagomirs (miRNA inhibitors) or miRNA mimics could represent a promising approach to manage diabetic complications [46,47].

THERAPEUTIC IMPLICATIONS AND FUTURE DIRECTIONS

The rising prevalence of diabetes, particularly type 2 diabetes (T2DM), necessitates innovative therapeutic strategies and comprehensive research efforts to improve management and outcomes. Recent advancements in understanding the epigenetic mechanisms underlying diabetes have opened new avenues for potential interventions [48]. Epigenetic modifications, such as DNA methylation and histone modifications, can influence gene expression related to insulin signaling, inflammation, and metabolic processes, offering targets for novel therapies [49].

Emerging Therapeutic Strategies

i. ***Epigenetic Modifiers:*** Targeting specific epigenetic modifications could provide new treatment options for diabetes. Drugs that alter DNA methylation patterns or histone acetylation may help restore normal gene expression in insulin-resistant tissues. Research into small molecules that can modulate these epigenetic marks is ongoing and holds promise for future diabetes therapies [50].

ii. ***Gene Therapy and Stem Cell Approaches:*** Advances in gene therapy techniques, including CRISPR/Cas9, allow for precise editing of genes involved in diabetes pathogenesis. Additionally, stem cell therapies aimed at regenerating insulin-producing β-cells present a potential cure for type 1 diabetes. Ongoing clinical trials are exploring these innovative approaches to restore normal insulin production [51].

iii. ***Digital Health Technologies:*** The integration of digital health technologies, such as continuous glucose monitoring and mobile health applications, is transforming diabetes management. These tools enhance patient engagement, facilitate real-time monitoring, and support personalized treatment plans, ultimately improving glycemic control and reducing complications [52].

iv. ***Pharmacological Innovations:*** New classes of medications, including GLP-1 receptor agonists and SGLT2 inhibitors, have demonstrated efficacy in improving glycemic control while also providing cardiovascular and renal protection [53]. Ongoing research is focused on developing additional agents that target various metabolic pathways to further enhance treatment options [54].

Future Research Directions

i. ***Longitudinal Studies:*** There is a need for long-term studies to better understand the effects of epigenetic modifications on diabetes progression and complications. Such studies could elucidate the mechanisms of "metabolic memory," where early glycemic control impacts long-term outcomes [55].

ii. ***Translational Research:*** Bridging the gap between basic research and clinical application is essential. Establishing biobanks and shared resources will facilitate access to human tissues and data, enabling researchers to validate findings and develop targeted therapies [56].

iii. ***Public-Private Partnerships:*** Collaborations between governmental agencies, academic institutions, and the pharmaceutical industry can accelerate the development and approval of new therapies. Such partnerships can enhance resource sharing and promote innovative research initiatives [57].

iv. ***Personalized Medicine:*** Future diabetes management strategies should focus on personalized approaches that consider genetic, epigenetic, and lifestyle factors. Tailoring interventions based on individual patient profiles could improve treatment efficacy and minimize adverse effects [58].

CONCLUSION

Understanding the interplay between epigenetic modifications and diabetes has significant implications for the prevention and management of this increasingly prevalent disease. This review highlights the critical role of epigenetic changes such as DNA methylation, histone modifications, and non-coding RNAs in the pathogenesis of type 2 diabetes (T2DM) and its complications. These modifications serve as a bridge between genetic predispositions and environmental influences, allowing for the regulation of gene expression in response to lifestyle factors such as diet and physical activity. The evidence suggests that epigenetic alterations contribute to the development of insulin resistance, β-cell dysfunction, and the progression of micro- and macrovascular complications associated with diabetes. Furthermore, the dynamic nature of these modifications presents opportunities for therapeutic intervention, as they are potentially reversible. Targeting specific epigenetic changes could lead to novel treatment strategies that enhance glycemic control and mitigate complications. Future research should focus on elucidating the complex mechanisms underlying epigenetic regulation in diabetes, exploring how lifestyle interventions can modify epigenetic marks, and identifying biomarkers for early detection of diabetic complications. By advancing our understanding of epigenetics in diabetes, we can pave the way for personalized medicine approaches that improve patient outcomes and quality of life.

REFERENCES

1. Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Sci Rep., 2024; 7(3):e2004. doi: 10.1002/hsr2.2004. PMID: 38524769; PMCID: PMC10958528.
2. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health., 2020; 10(1):107-111. doi: 10.2991/jegh.k.191028.001. PMID: 32175717; PMCID: PMC7310804.
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009 Jan;32 Suppl 1(Suppl 1): S62-7. doi: 10.2337/dc09-S062. PMID: 19118289; PMCID: PMC2613584.
4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;1(1):S67-74. doi: 10.2337/dc13-S067. PMID: 23264425; PMCID: PMC3537273.
5. Dilworth L, Facey A, Omoruyi F. Diabetes Mellitus and Its Metabolic Complications: The Role of Adipose Tissues. *International Journal of Molecular Sciences.* 2021; 22(14):7644. https://doi.org/10.3390/ijms22147644
6. M.C. Udeh Sylvester, O.F.C. Nwodo, O.E. Yakubu, E.J. Parker, S. Egba, E. Anaduaka, V.S. Tatah, O.P. Ugwu, E.M. Ale, C.M. Ude and T.J. Iornenge. Effects of Methanol Extract of *Gongronema latifolium* Leaves on Glycaemic Responses to Carbohydrate Diets in Streptozotocin-induced Diabetic Rats. Journal of Biological Sciences, 2022; 22: 70-79.
7. Ling C, Rönn T. Epigenetics in Human Obesity and Type 2 Diabetes. Cell Metab. 2019 May 7;29(5):1028-1044. doi: 10.1016/j.cmet.2019.03.009. Epub 2019 Apr 11. PMID: 30982733; PMCID: PMC6509280.
8. Macvanin MT, Gluvic Z, Bajic V, Isenovic ER. Novel insights regarding the role of noncoding RNAs in diabetes. World J Diabetes., 2023; 14(7):958-976. doi: 10.4239/wjd.v14.i7.958. PMID: 37547582; PMCID: PMC10401459.
9. Formichi C, Nigi L, Grieco GE, Maccora C, Fignani D, Brusco N, Licata G, Sebastiani G, Dotta F. Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases. Int J Mol Sci., 2021; 22(14):7716. doi: 10.3390/ijms22147716. PMID: 34299336; PMCID: PMC8306942.
10. Chanan Meydan, Nurcan Üçeyler, Hermona Soreq, Non-coding RNA regulators of diabetic polyneuropathy, Neuroscience Letters, 2020; 731, 135058, https://doi.org/10.1016/j.neulet.2020.135058.

11. Mrowicka M, Mrowicki J, Majsterek I. Relationship between Biochemical Pathways and Non-Coding RNAs Involved in the Progression of Diabetic Retinopathy. *Journal of Clinical Medicine*. 2024; 13(1):292. https://doi.org/10.3390/jcm13010292
12. Jakubik, D., Fitas, A., Eyileten, C. *et al.* MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics. *Cardiovasc Diabetol.*, 2021; **20**, 55. https://doi.org/10.1186/s12933-021-01245-2
13. Suárez R, Chapela SP, Álvarez-Córdova L, Bautista-Valarezo E, Sarmiento-Andrade Y, Verde L, Frias-Toral E, Sarno G. Epigenetics in Obesity and Diabetes Mellitus: New Insights. Nutrients, 2023; 15(4):811. doi: 10.3390/nu15040811. PMID: 36839169; PMCID: PMC9963127.
14. Ahmed SAH, Ansari SA, Mensah-Brown EPK, Emerald BS. The role of DNA methylation in the pathogenesis of type 2 diabetes mellitus. Clin Epigenetics., 2020; 12(1):104. doi: 10.1186/s13148-020-00896-4. PMID: 32653024; PMCID: PMC7353744.
15. Gareth W. Davison, Rachelle E. Irwin, Colum P. Walsh, The metabolic-epigenetic nexus in type 2 diabetes mellitus, Free Radical Biology and Medicine, 2021; 170: 194-206 https://doi.org/10.1016/j.freeradbiomed.
16. Suneesh Kaimala, Suraiya Anjum Ansari, Bright Starling Emerald, Chapter Six - DNA methylation in the pathogenesis of type 2 diabetes, Editor(s): Gerald Litwack, Vitamins and Hormones, Academic Press, 2023; 122, pp147-169. https://doi.org/10.1016/bs.vh.2022.11.002.
17. Parrillo L, Spinelli R, Nicolò A, Longo M, Mirra P, Raciti GA, Miele C, Beguinot F. Nutritional Factors, DNA Methylation, and Risk of Type 2 Diabetes and Obesity: Perspectives and Challenges. *International Journal of Molecular Sciences*. 2019; 20(12):2983. https://doi.org/10.3390/ijms20122983
18. Ugwu, O. P.C., **Alum, E. U.,**Okon, M. B., Aja, P. M., Obeagu, E. I. and Onyeneke, E. C. Ethanol root extract and fractions of *Sphenocentrum jollyanum* abrogate hyperglycemia and low body weight in Streptozotocin-induced diabetic Wistar albino Rats, *RPS Pharmacy and Pharmacology Reports*. 2023; 2,1-6.https://doi.org/10.1093/rpsppr/rqad010.
19. Johanne Tremblay, Pavel Hamet, Environmental and genetic contributions to diabetes, Metabolism, 2019; 100(s): 153952. https://doi.org/10.1016/j.metabol.2019.153952.
20. Mittal R, Camick N, Lemos JRN, Hirani K. Gene-environment interaction in the pathophysiology of type 1 diabetes. Front Endocrinol (Lausanne). 2024; 15:1335435. doi: 10.3389/fendo.2024.1335435. PMID: 38344660; PMCID: PMC10858453.
21. Sørensen, T.I.A., Metz, S. & Kilpeläinen, T.O. Do gene–environment interactions have implications for the precision prevention of type 2 diabetes? *Diabetologia*, 2022; **65**, 1804–1813. https://doi.org/10.1007/s00125-021-05639-5
22. Blanter, M., Sork, H., Tuomela, S. *et al.* Genetic and Environmental Interaction in Type 1 Diabetes: A Relationship Between Genetic Risk Alleles and Molecular Traits of Enterovirus Infection? *Curr Diab Rep.*, 2019; **19**, 82. https://doi.org/10.1007/s11892-019-1192-8
23. Li, Z., Ye, Cy., Zhao, TY. *et al.* Model of genetic and environmental factors associated with type 2 diabetes mellitus in a Chinese Han population. *BMC Public Health.*, 2020; **20**, 1024. https://doi.org/10.1186/s12889-020-09130-5
24. Goyal S, Rani J, Bhat MA, Vanita V. Genetics of diabetes. World J Diabetes. 2023 Jun 15;14(6):656-679. doi: 10.4239/wjd.v14.i6.656.
25. Chimaroke Onyeabo, Paul Anyiam Ndubuisi, Anthony Cemaluk Egbuonu, Prince Chimezie Odika, Simeon Ikechukwu Egba, Obedience Okon Nnana, Polycarp Nnacheta Okafor. Natural products-characterized Moringa oleifera leaves methanolic extract and anti-diabetic properties mechanisms of its fractions in streptozotocin-induced diabetic rats The Nigerian Journal of Pharmacy, 2022; 56(1) :18-29
26. Ng R, Sutradhar R, Yao Z, Wodchis WP, Rosella LC. Smoking, drinking, diet and physical activity-modifiable lifestyle risk factors and their associations with age to first chronic disease. Int J Epidemiol., 2020; 49(1):113-130. doi: 10.1093/ije/dyz078. PMID: 31329872; PMCID: PMC7124486.

27. Said MA, van de Vegte YJ, Zafar MM, van der Ende MY, Raja GK, Verweij N, van der Harst P. Contributions of Interactions Between Lifestyle and Genetics on Coronary Artery Disease Risk. Curr Cardiol Rep., 2019; 21(9):89. doi: 10.1007/s11886-019-1177-x. PMID: 31352625; PMCID: PMC6661028.
28. Jun-Yu Zhou, Sunmin Park Regular exercise, alcohol consumption, and smoking interact with the polygenetic risk scores involved in insulin sensitivity and secretion for the risk of concurrent hyperglycemia, hypertension, and dyslipidemia, Nutrition, 2021; 91-92, 111422.https://doi.org/10.1016/j.nut.2021.111422.
29. Marino P, Mininni M, Deiana G, Marino G, Divella R, Bochicchio I, Giuliano A, Lapadula S, Lettini AR, Sanseverino F. Healthy Lifestyle and Cancer Risk: Modifiable Risk Factors to Prevent Cancer. *Nutrients*. 2024; 16(6):800. https://doi.org/10.3390/nu16060800
30. Obeagu, E. I., Scott, G. Y., Amekpor, F., Ugwu, O. P. C., **Alum, E. U**. COVID-19 infection and Diabetes: A Current Issue. *International Journal of Innovative and Applied Research*. 2023; **11**(01): 25-30. DOI: 10.58538/IJIAR/2007. DOI URL: http://dx.doi.org/10.58538/IJIAR/2007.
31. Nilsson EE, Ben Maamar M, Skinner MK. Role of epigenetic transgenerational inheritance in generational toxicology. Environ Epigenet. 2022 Feb 16;8(1): dvac001. doi: 10.1093/eep/dvac001. PMID: 35186326; PMCID: PMC8848501.
32. Jennifer J. Tuscher, Jeremy J. Day, Multigenerational epigenetic inheritance: One step forward, two generations back, Neurobiology of Disease, 2019; 132, 104591
33. Ugwu, O. P. C., Alum, E. U. and Uhama, K. C. Dual Burden of Diabetes Mellitus and Malaria: Exploring the Role of Phytochemicals and Vitamins in Disease Management. Research Invention Journal of Research in Medical Sciences. 2024; 3(2):38-49.
34. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I. Beyond Pregnancy: Understanding the Long-Term Implications of Gestational Diabetes Mellitus. *INOSR Scientific Research*. 2024; 11(1):63-71.https://doi.org/10.59298/INOSRSR/2024/1.1.16371
35. Bansal A, Pinney SE. DNA methylation and its role in the pathogenesis of diabetes. Pediatr Diabetes, 2017; 18(3):167-177. doi: 10.1111/pedi.12521. PMID: 28401680; PMCID: PMC5394941.
36. Suárez R, Chapela SP, Álvarez-Córdova L, Bautista-Valarezo E, Sarmiento-Andrade Y, Verde L, Frias-Toral E, Sarno G. Epigenetics in Obesity and Diabetes Mellitus: New Insights. Nutrients, 2023; 15(4):811. doi: 10.3390/nu15040811. PMID: 36839169; PMCID: PMC9963127.
37. Ahmed, S.A.H., Ansari, S.A., Mensah-Brown, E.P.K. *et al.* The role of DNA methylation in the pathogenesis of type 2 diabetes mellitus. *Clin Epigenet*, 2020; **12**, 104. https://doi.org/10.1186/s13148-020-00896-4
38. Roberta Giordo, Anna Maria Posadino, Arduino Aleksander Mangoni, Gianfranco Pintus, Metformin-mediated epigenetic modifications in diabetes and associated conditions: Biological and clinical relevance, Biochemical Pharmacology, 2023; 215, 115732 https://doi.org/10.1016/j.bcp.2023.115732.
39. Jun-Yu Deng, Xing-Qian Wu, Wen-Jie He, Xin Liao, Ming Tang, Xu-Qiang Nie, Targeting DNA methylation and demethylation in diabetic foot ulcers, Journal of Advanced Research, 2023; 54, 119-131. https://doi.org/10.1016/j.jare.2023.01.009.
40. Cerna M. Epigenetic Regulation in Etiology of Type 1 Diabetes Mellitus. *International Journal of Molecular Sciences*. 2020; 21(1):36. https://doi.org/10.3390/ijms21010036
41. Uhuo E N, Egba S I, Nwuke P C, Obike C A and Kelechi G K. Antioxidative properties of Adansonia digitata L. (baobab) leaf extract exerts protective effect on doxorubicin induced cardiac toxicity in Wistar rats. Clinical Nutrition Open Science, 2022; 45:3-16
42. Gilyazova I, Asadullina D, Kagirova E, Sikka R, Mustafin A, Ivanova E, Bakhtiyarova K, Gilyazova G, Gupta S, Khusnutdinova E, Gupta H, Pavlov V. MiRNA-146a-A Key Player in Immunity and Diseases. Int J Mol Sci. 2023; 24(16):12767. doi: 10.3390/ijms241612767. PMID: 37628949; PMCID: PMC10454149.
43. Seyed Mohsen Aghaei-Zarch, Crosstalk between MiRNAs/lncRNAs and PI3K/AKT signaling pathway in diabetes mellitus: Mechanistic and therapeutic perspectives, Non-coding RNA Research, 2024; 9(2): 486-507. https://doi.org/10.1016/j.ncrna.2024.01.005.

44. Tang, Y., Zong, S., Zeng, H. *et al.* MicroRNAs and angiogenesis: a new era for the management of colorectal cancer. *Cancer Cell Int* **21**, 221 (2021). https://doi.org/10.1186/s12935-021-01920-0
45. Rajeswari Raguraman, Akhil Srivastava, Anupama Munshi, Rajagopal Ramesh, Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer, Advanced Drug Delivery Reviews, 2021; 178, 113918. https://doi.org/10.1016/j.addr.2021.113918.
46. Ugwu, O.P.C., Kungu, E., Inyangat, R., Obeagu, E. I., Alum, E. U., Okon, M. B., Subbarayan, S. and Sankarapandiyan, V. Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda: Ethnobotanical Insights, Pharmacotherapeutic Strategies, and National Development Alignment. INOSR Experimental Sciences, 2023; 12(2):214-224. https://doi.org/10.59298/INOSRES/2023/2.17.1000.
47. Ling C, Rönn T. Epigenetics in Human Obesity and Type 2 Diabetes. Cell Metab. 2019; 29(5):1028-1044. doi: 10.1016/j.cmet.2019.03.009. Epub 2019 Apr 11. PMID: 30982733; PMCID: PMC6509280.
48. Eze Chukwuka W., Egba **Simeon,** Nweze Emeka I., Ezeh Richard C. and Ugwu dike Patrick. Ameliorative Effects of *Allium cepa* and *Allium sativum* on Diabetes Mellitus and Dyslipidemia in Alloxan-induced Diabetic *Rattus novergicus*. *Trends Applied Sci Res*, 2020; **15(2):** 145-150
49. Antonella Farsetti, Barbara Illi, Carlo Gaetano, how epigenetics impacts on human diseases, European Journal of Internal Medicine, 2023; 114, 15-22. https://doi.org/10.1016/j.ejim.2023.05.036.
50. Abubakar B, Usman D, Sanusi KO, Azmi NH, Imam MU. Preventive Epigenetic Mechanisms of Functional Foods for Type 2 Diabetes. *Diabetology*. 2023; 4(3):259-277. https://doi.org/10.3390/diabetology4030023
51. Elliott, H.R., Sharp, G.C., Relton, C.L. *et al.* Epigenetics and gestational diabetes: a review of epigenetic epidemiology studies and their use to explore epigenetic mediation and improve prediction. *Diabetologia*, 2019; **62**, 2171–2178. https://doi.org/10.1007/s00125-019-05011-8
52. Fatima A, Rasool S, Devi S, Talha M, Waqar F, Nasir M, Khan MR, Ibne Ali Jaffari SM, Haider A, Shah SU, Sapna F, Varrassi G, Khatri M, Kumar S, Mohamad T. Exploring the Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Expanding Horizons Beyond Diabetes Management. Cureus. 2023; 15(9):e46243. doi: 10.7759/cureus.46243. PMID: 37908957; PMCID: PMC10613932.
53. Rolek B, Haber M, Gajewska M, Rogula S, Pietrasik A, Gąsecka A. SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain. J Cardiovasc Dev Dis. 2023; 10(8):322. doi: 10.3390/jcdd10080322. PMID: 37623335; PMCID: PMC10455499.
54. Seidu, S., Alabraba, V., Davies, S. *et al.* SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review. *Diabetes Ther*, 2024; **15**, 1099–1124. https://doi.org/10.1007/s13300-024-01550-5
55. Gourdy, P., Darmon, P., Dievart, F. *et al.* Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). *Cardiovasc Diabetol* **22**, 2023; 79. https://doi.org/10.1186/s12933-023-01798-4
56. Clara Luna-Marco, Francesca Iannantuoni, Alberto Hermo-Argibay, Deédeni Devos, Juan D. Salazar, Víctor M. Víctor, Susana Rovira-Llopis, Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress, Free Radical Biology and Medicine, 2024; 213, 19-35. https://doi.org/10.1016/j.freeradbiomed.2024.01.015.
57. Ahmad, A., Sabbour, H. Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies. *Cardiovasc Diabetol* 2024; **23**, 99. https://doi.org/10.1186/s12933-024-02192-4

CITE AS: Kato Jumba K. (2024). Epigenetic Modifications and Diabetes: Unraveling the Interplay between Genetics, Lifestyle, and Disease Progression. RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY 3(3): 1-9. https://doi.org/10.59298/RIJPP/2024/3319